Deal-Making Trends in Pharma - Thematic Research
Summary
To gain a better understanding of the pharmaceutical deal landscape, this report will dive into three separate deal categories: strategic partnerships, licensing activity, and M&A activity. Furthermore, the categories will be further broken down by four dominating therapeutic themes. These include gene therapy, immuno-oncology, microbiome, and orphan drugs.
These themes are among those expected to have the greatest presence in deals made within the pharmaceutical industry, which is indicative of the optimism surrounding their future potential. Please also note that this report only covers select geographies, North America, Europe, and Asia-Pacific, the three regions with the highest deal volume and value. These regions were also chosen to be covered in this report based on the fact that they are hotspots for the development of innovative drugs.
This report also identifies target drug companies that would be strong acquisition target candidates.
The companies identified include those that have drugs that fall into one of the four major themes discussed in this report: gene therapy, immuno-oncology, microbiome, and/or orphan drugs. Chosen targets were also selected on the basis of having drugs in both the preclinical stage and clinical stage settings. Identified targets are also all privately owned, and have seen little to no recent merger and acquisition (M&A) activity in the past five years. Lastly, the list of targets also includes those have had recent positive clinical trial data.
Scope
The author’s Deal-Making Trends in Pharma report provides with in-house expertise to provide an assessment of the deal landscape within the pharmaceutical industry.
Components of the report include -
Reasons to Buy
Summary
To gain a better understanding of the pharmaceutical deal landscape, this report will dive into three separate deal categories: strategic partnerships, licensing activity, and M&A activity. Furthermore, the categories will be further broken down by four dominating therapeutic themes. These include gene therapy, immuno-oncology, microbiome, and orphan drugs.
These themes are among those expected to have the greatest presence in deals made within the pharmaceutical industry, which is indicative of the optimism surrounding their future potential. Please also note that this report only covers select geographies, North America, Europe, and Asia-Pacific, the three regions with the highest deal volume and value. These regions were also chosen to be covered in this report based on the fact that they are hotspots for the development of innovative drugs.
This report also identifies target drug companies that would be strong acquisition target candidates.
The companies identified include those that have drugs that fall into one of the four major themes discussed in this report: gene therapy, immuno-oncology, microbiome, and/or orphan drugs. Chosen targets were also selected on the basis of having drugs in both the preclinical stage and clinical stage settings. Identified targets are also all privately owned, and have seen little to no recent merger and acquisition (M&A) activity in the past five years. Lastly, the list of targets also includes those have had recent positive clinical trial data.
Scope
The author’s Deal-Making Trends in Pharma report provides with in-house expertise to provide an assessment of the deal landscape within the pharmaceutical industry.
Components of the report include -
- Data analysis, trends, and insights for strategic partnerships, licensing activity, and M&A activity within the pharmaceutical industry
- Data analysis, trends, and insights for deals that encompass specific therapeutic themes (gene therapy, immuno-oncology, microbiome, and orphan drugs)
- Data analysis, trends, and insights for deals that have occurred in select geographies (North America, Europe, and Asia-Pacific)
- Identification of drug companies that would be strong acquisition target candidates
Reasons to Buy
- Gain a better understating of the volume and value dynamics within the pharmaceutical deal space.
- Stay up to date on the industry’s most impactful deals that have been completed within the past 5 years, along with a glimpse of deals completed or to be completed in 2019.
- Identify emerging deal trends, as they relate to deal type, therapeutic theme, geography, to gain a competitive advantage.
- Identify drug companies that would be strong acquisition target candidates.
Table of Contents
1 Table of Contents
2 Introduction
3 Deal-Making and the Importance of Themes
4 Strategic Partnership Activity over the Last Five Years
5 Licensing Activity over the Last Five Years
6 Merger and Acquisition Activity over the Last Five Years
7 What Does It Mean?
9 Appendix: Our “Thematic” Research Methodology
List of Tables
List of Figures
